biotech 2050

@Biotech2050

No investment advice. Do your own DD Market is all about taking the shares from the weak holders& providing opportunities to those that have the stamina to hold

Vrijeme pridruživanja: travanj 2014.

Tweetovi

Blokirali ste korisnika/cu @Biotech2050

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Biotech2050

  1. Prikvačeni tweet
    1. sij
    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet
    prije 8 sati

    Biogen extends gains to more than 28%, now on pace for its best day ever

    Prikaži ovu nit
    Poništi
  3. proslijedio/la je Tweet
    prije 12 sati
    Odgovor korisniku/ci

    sb-525 phase 3 lead in already

    Poništi
  4. proslijedio/la je Tweet
    prije 13 sati

    27.8m shares price at $3.25/share

    Poništi
  5. proslijedio/la je Tweet
    prije 13 sati

    The take home messages from one of the symposia on gene therapy in at . Excellent session.

    Poništi
  6. proslijedio/la je Tweet
    prije 13 sati

    Comments about the longer term impact of gene therapy in .

    Poništi
  7. proslijedio/la je Tweet
    prije 13 sati

    The gene therapy journey for a patient is not just the vector infusion.

    Poništi
  8. proslijedio/la je Tweet
    prije 13 sati

    Who can argue against the need for reliable information to decide whether patients go for gene therapy in

    Poništi
  9. proslijedio/la je Tweet
    Odgovor korisnicima

    with gene therapy durability will always be limited to some kind ... ultimate goal will be to make a permenant fix with gene editing Sangamo ZFN 2.0 trial starts year end , will do this in hemophilia B

    Poništi
  10. proslijedio/la je Tweet

    Question from Pasi at About 25% of patients have asked for information about Gene Therapy

    Poništi
  11. proslijedio/la je Tweet

    Pasi at question on Gene Therapy expression level. Largest group want 30% to 50% Question on duration of expression. Largest group want 10 to 15 years. Several GT companies asking these questions at the Conference

    Poništi
  12. proslijedio/la je Tweet
    Poništi
  13. proslijedio/la je Tweet

    Graphical representation of FIX and FVII Gene Therapy by Pasi at

    Poništi
  14. proslijedio/la je Tweet
    prije 16 sati

    upgraded to Overweight from Neutral at Piper. PT $27 from $18

    Poništi
  15. proslijedio/la je Tweet
    prije 23 sata

    HCW the regulatory submission for Neutrolin could be completed in 1H20, with approval in 2H20 under a Priority Review timeline. We reiterate our Buy rating and 12-month target of $14.00 on CorMedix shares.

    Poništi
  16. proslijedio/la je Tweet
    4. velj

    Liverpool 1-0 Shrewsbury // Goal

    Poništi
  17. proslijedio/la je Tweet
    4. velj

    Did you really think Jurgen Klopp was on holiday?

    Poništi
  18. proslijedio/la je Tweet
    4. velj

    Ziopharm to Offer Shares Said at $3.25/Share

    Poništi
  19. 4. velj
    Poništi
  20. proslijedio/la je Tweet
    4. velj

    is emphasizing and more in quarterly reporting. Let's see how compares tonight.

    Poništi
  21. 4. velj

    Is Respiratory syncytial virus the undisclosed infectious disease pipeline which will partner? See slide page 4 (Genvec was acquired by Intrexon. Interestingly they are looking into editing )

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·